Comparative Pharmacology
Head-to-head clinical analysis: PARCOPA versus STALEVO 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARCOPA versus STALEVO 125.
PARCOPA vs STALEVO 125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbidopa inhibits decarboxylation of levodopa in the periphery, increasing levodopa availability to the brain. Levodopa is converted to dopamine in the CNS, replenishing dopamine levels in the striatum.
Stalevo 125 is a combination of carbidopa, levodopa, and entacapone. Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its availability to the brain. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), primarily in the periphery, which reduces the metabolism of levodopa to 3-O-methyldopa, prolonging the half-life of levodopa.
0.5 mg orally three times daily, titrated slowly based on response and tolerability; maximum 8 mg/day.
One tablet of STALEVO 125 (levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg) orally, one tablet per dose, up to maximum 10 tablets per day. Frequency: typically every 4-6 hours while awake, adjusted based on response.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-3 hours; in elderly patients, half-life may be prolonged due to reduced renal clearance, requiring dose adjustment.
Levodopa: 1-3 hours (short half-life necessitates frequent dosing with carbidopa to reduce peripheral metabolism). Carbidopa: 1-2 hours (not clinically significant alone). Entacapone: 0.4-0.7 hours (short half-life; acts primarily during absorption phase of levodopa).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Levodopa: renal excretion of metabolites (dopamine, DOPAC, HVA) accounts for >70% of dose; <1% unchanged. Carbidopa: renal excretion of unchanged drug (~30%) and metabolites (~70%). Entacapone: primarily fecal excretion (~90%) with ~10% renal; entacapone glucuronide and unchanged drug in urine.
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent